Swedish Orphan Biovitrum
185 articles with Swedish Orphan Biovitrum
-
Swedish Orphan Biovitrum AB (Sobi) has received an $8 billion (68 billion kronor) cash buyout offer from Advent International, valuing its shares at SEK 235 each.
-
Invitation - Presentation of Sobi's Q2 2021 results
7/8/2021
On 21 July, at 08:00 CEST, Swedish Orphan Biovitrum AB will publish its report for the second quarter 2021.
-
Sobi to present data at the ISTH 2021 within rare haematology diseases
7/7/2021
Swedish Orphan Biovitrum AB presents data at the virtual ISTH 2021, the 29th Congress of the International Society on Thrombosis and Haemostasis, 17 – 21 July 2021.
-
Sobi at EHA virtual congress 2021: focus on results in PNH and treatment for ITP
6/1/2021
Swedish Orphan Biovitrum AB will present data at the EHA virtual congress, 9-17 June 2021, highlighting the company's advancement of treatments for rare haematological diseases.
-
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
5/25/2021
- Pegcetacoplan demonstrated statistical superiority on the co-primary endpoints of haemoglobin stabilisation (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which did not include complement inhibitors, at week 26 - Mean haemoglobin levels in the pegcetacoplan group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019)
-
Invitation - Presentation of Sobi's Q1 2021 results
4/26/2021
On 4 May, at 08:00 CEST, Swedish Orphan Biovitrum AB will publish its report for the first quarter 2021.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH
3/17/2021
Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in haemoglobin levels and showed improvements in key clinical outcomes
-
First patient dosed in phase 3 study with avatrombopag for treatment of ITP in children
3/12/2021
Swedish Orphan Biovitrum AB announces that the first patient has been dosed with avatrombopag, a thrombopoietin receptor agonist, for treatment of immune thrombocytopenia in pediatric patients.
-
Rare Disease Day 2021: Pandemic illuminates every day social obstacles of living with a rare condition
2/26/2021
40 per cent of Swedes with a rare condition, or their family members, state that a relationship has ended due to a rare condition, according to a study by Swedish biopharmaceutical company Sobi.
-
Sobi publishes report for the fourth quarter and full-year 2020
2/18/2021
Swedish Orphan Biovitrum AB announces its results for the fourth quarter and full-year 2020.
-
Kineret® (anakinra) approved in Russia for the treatment of CAPS
2/16/2021
Swedish Orphan Biovitrum AB announces that the Ministry of Health of the Russian Federation has approved Kineret for the treatment of Cryopyrin associated periodic syndromes.
-
Invitation - Presentation of Sobi's Q4 and FY 2020 results
2/3/2021
On 18 February, at 08:00 CET, Swedish Orphan Biovitrum AB will publish its report for the forth quarter and full-year 2020.
-
Doptelet® (avatrombopag) approved in the EU for treatment of ITP
1/20/2021
Swedish Orphan Biovitrum AB announces that the European Commission has approved an extension of the indication for Doptelet to include the treatment of primary chronic immune thrombocytopenia in adult patients who are refractory to other treatments in all European Union member states.
-
Sobi appoints new Head of North America ahead of launch phase
12/21/2020
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI ) has appointed Duane Barnes as the new Head of Sobi in North America . "Sobi in North America has gone through significant change over the past few years and has exciting launches both underway and coming up in the years ahead," says Guido Oelkers , CEO and President of S
-
Emapalumab submission in China for primary HLH
12/10/2020
Swedish Orphan Biovitrum AB announced that a Marketing Authorization Application for emapalumab has been accepted for review in China.
-
Realising opportunities for future growth and financial update: Sobi Capital Markets Day 2020
12/10/2020
Swedish Orphan Biovitrum AB is hosting a virtual Capital Markets Day . Presentations from senior management will showcase Sobi's strategy for growth in the core areas of Immunology and Haematology, strengthening its pipeline, extending its geographical footprint and expanding growth opportunities.
-
Agenda: Sobi Capital Markets Day 2020
12/7/2020
Swedish Orphan Biovitrum AB is pleased to invite analysts, investors and media to its Virtual Capital Markets Day on 10 December 2020 at 13:00-16:00 CET.
-
Strong Sobi presence at American Society of Hematology 2020 Annual Meeting
11/6/2020
Sobi™ will present data at the 62nd Annual Meeting of the American Society of Hematology taking place taking place as a virtual meeting from 5-8 December.
-
Sobi launch Doptelet® (avatrombopag) in Europe
11/4/2020
Sobi™ Swedish Orphan Biovitrum AB announced the commercial launch of Doptelet® in Europe, with the United Kingdom as the first country for launch.